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Naci and colleagues rightly point out that although drugs are
often approved on the basis of glucose lowering efficacy, we
really need agents that reduce important outcomes such as
symptomatic microvascular disease and cardiovascular events.1
The authors suggest that real world evidence of clinical
effectiveness should be required from the drug industry, using
routine healthcare data to monitor outcomes.
At the University of Surrey we have entered into partnership
with Eli Lilly to provide some of these essential outcomes data
using primary care records. Our preliminary analysis further
highlights the need to extend studies into the real world. In
practice people treated with glucagon-like peptide-1 (GLP1)
agonists and sodium-glucose co-transporter-2 (SGLT2)
inhibitors have a significantly higher body mass index than
those in clinical trials (GLP1 agonists: 37.5 in practice, 31.8 in
aggregated trials; P<0.001; SGLT2 inhibitors: 34.7 in practice,
30.6 in trials; P<0.001). Trial populations are not representative
of the people treated with these new drugs, and the effectiveness
in practice may be less certain.
If this investigation into real world outcomes is to be funded by
the drug industry, stringent precautions must be taken to
minimise the biases identified in industry funded research.2
Non-trial research should be registered in a similar way to
clinical trials, with demands for high quality research protocols
to be recorded before data extraction and analysis.
We agree that drug outcomes data must include outcomes
relevant to patients. Only well constructed studies in the real
world will confirm the effectiveness of new and existing drugs.
Competing interests: AMcG, NM, and SdeL undertake research as part
of the newly developed University of Surrey-Lilly Real World Evidence
Centre funded by Eli Lilly and Company. RH has no competing interests
to declare.
Full response at: www.bmj.com/content/351/bmj.h5260/rr-0.
1 Naci H, Lehman R, Wouters OJ, et al. Rethinking the appraisal and approval of drugs for
type 2 diabetes. BMJ 2015;351:h5260. (9 October.)
2 Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research
outcome and quality: systematic review. BMJ 2003;326:1167-70.
Cite this as: BMJ 2015;351:h5829
© BMJ Publishing Group Ltd 2015
andy@mcgov.co.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;351:h5829 doi: 10.1136/bmj.h5829 (Published 3 November 2015) Page 1 of 1
Letters
LETTERS
